Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A.
Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
Eli Lilly, the Indianapolis-based drugmaker behind pharmaceuticals such as Mounjaro, acquired the 84,000-square-foot facility at 10300 128th Ave. from Nexus in April 2024 with plans to use the ...
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...
Indianapolis-based Eli Lilly and Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors such alcohol abuse, smoking and drug ...
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic ...
Hosted on MSN17d
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment ... hesitated to cover ...
LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...
Macupatide (LY-3532226) is under development for the treatment of type 2 diabetes, obesity and type 1 diabetes mellitus. It is administered through subcutaneous route. It is a long acting new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback